Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Blood

Volumn 124, Issue 11, 2014, Pages 1715-1726

  Noris, Marina ^a,b   Galbusera, Miriam ^a,b   Gastoldi, Sara ^a,b   Macor, Paolo ^c   Banterla, Federica ^a,b   Bresin, Elena ^a,b   Tripodo, Claudio ^d   Bettoni, Serena ^a,b   Donadelli, Roberta ^a,b   Valoti, Elisabetta ^a,b   Tedesco, Francesco ^e   Amore, Alessandro ^f   Coppo, Rosanna ^f   Ruggenenti, Piero ^g   Gotti, Eliana ^g   Remuzzi, Giuseppe ^a,b,g  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Centro Anna Maria Astori Science and Technology Park Kilometro Rosso   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^f REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^g Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; ADENOSINE DIPHOSPHATE RIBOSE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CASE REPORT; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; END STAGE RENAL DISEASE; ENDOTHELIUM; EX VIVO STUDY; FEMALE; GENE MUTATION; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; IMMUNE COMPLEX DISEASE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT; BLOOD; CLINICAL TRIAL; DRUG EFFECT; ENDOTHELIUM CELL; METABOLISM; PATHOLOGY; PHYSIOLOGIC MONITORING; TIME;

ADENOSINE DIPHOSPHATE RIBOSE; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENDOTHELIAL CELLS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MONITORING, PHYSIOLOGIC; REMISSION INDUCTION; TIME FACTORS;

EID: 84908611206     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-558296     Document Type: Article

References (37)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17): 1676-1687.
2. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10): 1844-1859.
3. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007;104(1):240-245.
4. Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008; 112(13):4948-4952.
5. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4): 345-357.
6. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2): 379-387.
7. Bresin E, Rurali E, Caprioli J, et al; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24(3): 475-486.
8. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest. 2003;111(8):1181-1190.
9. Roumenina LT, Jablonski M, Hue C, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood. 2009;114(13):2837-2845.
10. Pickering MC, de Jorge EG, Martinez-Barricarte R, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204(6): 1249-1256.
11. de Jorge EG, Macor P, Paixão-Cavalcante D, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol. 2011;22(1):137-145.
12. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
13. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23):2169-2181.
14. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8(11):622-633.
15. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11): 643-657.
16. Barrow M. Health chiefs refuse to pay for livesaving kidney treatment. The Times; May 27, 2013.
17. Laurance J. At what cost? Live saving drug withheld. The Independent; May 26, 2013.
18. Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531-536.
19. Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079-1089.
20. Licht C, Heinen S, Józsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006;70(1):42-50.
21. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest. 2010;120(10): 3702-3712.
22. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871-879.
23. Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187(1):172-180.
24. Valoti E, Alberti M, Tortajada A, et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation [published online June 5, 2014]. J Am Soc Nephrol.
25. Richards A, Buddles MR, Donne RL, et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet. 2001;68(2): 485-490.
26. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(8): 1325-1329.
27. Martinez-Barricarte R, Pianetti G, Gautard R, et al; European Working Party on the Genetics of HUS. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2008;19(3): 639-646.
28. Ring T. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;369(14): 1377-1378.
29. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol. 2004;41(1):81-84.
30. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365(1-2):8-26.
31. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508-530.
32. Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Mol Immunol. 2007;44(16):3889-3900.
33. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119(18):4182-4191.
34. Sullivan M, Rybicki LA, Winter A, et al. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet. 2011;75(6):639-647.
35. Sullivan M, Erlic Z, Hoffmann MM, et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet. 2010;74(1):17-26.
36. Tanimoto T, Oshima Y, Kami M. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;369(14):1378-1379.
37. Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;369(14):1379-1380.